Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-07-23 |
2024-06 |
-0.09 |
N/A |
N/A |
N/A |
2024-04-23 |
2024-03 |
-0.14 |
-0.25 |
-0.11 |
-78.57% |
2024-02-28 |
2023-12 |
-0.11 |
0.04 |
0.15 |
136.36% |
2024-02-28 |
2023-12 |
-0.11 |
N/A |
N/A |
N/A |
2023-10-31 |
2023-09 |
-0.18 |
N/A |
N/A |
N/A |
2023-10-31 |
2023-09 |
-0.18 |
-0.2 |
-0.02 |
-11.11% |
Date |
Firm |
Action |
From |
To |
2023-07-25 |
Goldman Sachs |
Upgrade |
Buy |
Buy |
2023-03-08 |
JP Morgan |
Upgrade |
|
Overweight |
2021-12-28 |
B of A Securities |
Upgrade |
|
Buy |
2020-03-31 |
B of A Securities |
Upgrade |
|
Buy |
2020-03-10 |
JP Morgan |
Upgrade |
|
Overweight |
2019-12-05 |
Goldman Sachs |
Upgrade |
Neutral |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-06-28 |
COLE GORDON BRADLEY |
Director |
5.00K |
Conversion of Exercise of derivative security |
2024-05-02 |
LEVY RICHARD S |
Director |
8.52K |
Conversion of Exercise of derivative security |
2024-04-07 |
MEGNA MICHAEL R |
Officer |
21.33K |
Conversion of Exercise of derivative security |
2024-04-07 |
MOAT ROSS |
Officer |
16.28K |
Conversion of Exercise of derivative security |
2024-04-07 |
PAOLINI JOHN F |
Officer |
47.80K |
Conversion of Exercise of derivative security |
2024-04-07 |
PATEL SANJIV K |
Chief Executive Officer |
172.81K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Rubric Capital Management LP |
3.38M |
47.56M |
9.59% |
2023-06-29 |
Blackrock Inc. |
3.16M |
44.50M |
8.97% |
2023-06-29 |
Vanguard Group Inc |
3.09M |
43.47M |
8.76% |
2023-06-29 |
Baker Brothers Advisors, LLC |
2.81M |
39.56M |
7.97% |
2023-06-29 |
State Street Corporation |
1.65M |
23.26M |
4.69% |
2023-06-29 |
Pictet Asset Management SA |
1.52M |
21.36M |
4.31% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
1.01M |
17.32M |
2.85% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
893.71K |
12.58M |
2.54% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
812.59K |
11.44M |
2.31% |
2023-08-30 |
iShares Russell 2000 ETF |
710.85K |
12.25M |
2.02% |
2023-06-29 |
Vanguard Small Cap Value Index Fund |
562.69K |
7.92M |
1.60% |
2023-06-29 |
Meridian Small Cap Growth Fund |
416.26K |
5.86M |
1.18% |